Health Care

Brokerage Recent Rating Update: Gilead Sciences, Inc. (NASDAQ:GILD), Relypsa, Inc. (NASDAQ:RLYP)

0 132

Gilead Sciences, Inc. (NASDAQ:GILD) initiated the shares trading at $85.35 and showed positive change of +1.43% while the stock’s final trade was registered at $ 86.66. However, its previous closing price was seen at $85.44. The stock negotiated total number of 9.06 million shares as compared to 3 months average volume of 9.49 million shares.

The stock price demonstrated downbeat change from its 50 day moving average of 84.65 and had been down from its 200 Day Moving Average of 89.11.

The average true range of Gilead Sciences Inc.’s (GILD) is recorded at 1.73 and the relative strength index of the stock stands 58.19. The stock price is going above to its 52 week low with 11.22% and lagging behind from its 52 week high with -26.65%. Analyst recommendation for this stock stands at 2.10. A look on the firm performance, its monthly performance is 4.42% and a quarterly performance of -12.95%. The stock price is trading downbeat from its 200 days moving average with -6.84% and up from 50 days moving average with 2.84%.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. One week ago, shares have been suggested as “BUY” from “7” brokerage firms and recommended as “Strong Buy” by “2” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1.94” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

Shares of Relypsa, Inc. (NASDAQ:RLYP) climbed +1.31% and ended at $20.10 greater than previous closing price of $19.84. The total 1.25 million shares were bought and sold throughout the most recent trading session less than average volume of 2.81 million shares.

Galenica Group (GALN.VX) and Relypsa, Inc. (RLYP) reported that the companies have entered into a definitive contract under which Galenica will acquire Relypsa. This transaction further strengthens Galenica’s Business unit, Vifor Pharma, as the firmwill gain full global rights to the potassium binder Veltassa® (patiromer) for oral suspension and enhance its growing position as a global specialty pharmaceutical company. Under the terms of the merger contract, Galenica will pay $32 per share in cash, or a total of about $1.53 billion. Through this acquisition, Vifor Pharma will gain a fully-integrated commercial organization in the United States and importantly strengthen its presence in the U.S. cardio-renal market, a key area of focus.

Relypsa, Inc.’s (RLYP) has price-to-cash ratio of 4.23 and price to sale ratio of 28.06. The company gross profit margin is 99.70%. A look on the firm performance, its monthly performance is 15.38% and a quarterly performance of 15.12%. The stock price is moving up from its 20 days moving average with 6.55% and isolated positively from 50 days moving average with 12.76%.

Brokerage Recommendations:

According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. One week ago, shares have been suggested as “BUY” from “2” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 1” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1.66” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.

 

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

Advirtisement

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter